Telehealth Stumbles While Global Biotech Advances

Summary

The medical and telehealth industries are seeing rapid shifts, starting with a stumble for digital health platform Hims. The company recently missed its sales targets, a drop driven by stiffening competition in the expanding telehealth market. Meanwhile, traditional pharmaceutical companies are forging major new global partnerships. Bristol Myers Squibb has teamed up with Chinese drugmaker Hengrui Pharma to replenish its drug pipeline. However, this partnership comes with an important caveat, as the more than a dozen programs included in the deal are still in the very early stages of development.

On the clinical front, patients are seeing new treatment options advance. Rigel Pharma has secured a deal with Arvinas and Pfizer to commercialize a newly approved breast cancer drug called Veppanu. Across the regulatory desk, BridgeBio has officially asked the Food and Drug Administration to approve encaleret. This medication is designed to treat autosomal dominant hypocalcemia type 1, often called ADh2, which is a rare genetic disease.

Finally, in a significant step for neurological care, Roche has secured regulatory clearance in Europe for a new diagnostic tool. The company has successfully developed a blood test specifically designed to detect Alzheimer's disease in its early stages.

Why it matters.

These developments highlight two major trends in modern medicine: the globalization of drug development and the push for earlier diagnostics. The partnership between Bristol Myers Squibb and Hengrui Pharma illustrates how Western pharmaceutical companies are looking to China to find future therapies. Even though these dozen-plus specific programs are early in their development, this strategy is vital for companies needing to stay competitive. Similarly, the growing competition squeezing telehealth companies like Hims shows that digital medicine is maturing into a fiercely contested business landscape.

For patients, the most immediate impacts come from the new treatments and diagnostics moving through regulatory channels. An approved blood test for early Alzheimer's disease represents a significant step forward in how doctors might screen for the condition before symptoms become severe. Meanwhile, the steady march of targeted therapies, from newly approved breast cancer drugs to specialized treatments for rare genetic diseases like ADh2, promises to bring highly specific care to patient populations that urgently need new options.

From the source

The story in numbers.

Early-stage programs in BMS and Hengrui Pharma partnership: >12
Type of autosomal dominant hypocalcemia targeted by BridgeBio's FDA application: 1

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

Telehealth Stumbles While Global Biotech Advances

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.